Online citations, reference lists, and bibliographies.
← Back to Search

Detection Of Covalent Adducts To Cytochrome P450 3A4 Using Liquid Chromatography Mass Spectrometry.

K. Bateman, Jennifer L Baker, M. Wilke, Justin Lee, T. Leriche, C. Seto, S. Day, N. Chauret, M. Ouellet, D. Nicoll-Griffith
Published 2004 · Chemistry, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Protein covalent labeling can be an undesirable property of compounds being studied in drug discovery programs. Identifying such compounds relies on the use of radiolabeled material, which requires an investment in time and resources not typically expended until later in the discovery process. We describe the detection of covalent adducts to cytochrome P450 3A4, the most abundant and important P450 from a human and drug discovery viewpoint, using liquid chromatography mass spectrometry. The technique is illustrated using L-754,394 and 6',7'-dihydroxybergamottin, two known inhibitors of P450 3A4. Mass spectrometry of the intact apoprotein as well as the adducted protein is demonstrated. Such methodology may provide the means for screening compounds for covalent protein binding without the use of a radiolabel. It also provides direct information about mechanism-based inhibitors in terms of extent, stoichiometry, and nature of the adduct(s) (mass shift). This information may provide a means for understanding the mechanism of covalent labeling earlier in a drug discovery environment.
This paper references
10.1021/TX00009A001
Covalent bonding of the prosthetic heme to protein: a potential mechanism for the suicide inactivation or activation of hemoproteins.
Y. Osawa (1989)
Suicide inactivation of cytochrome P-450 by methoxsalen. Evidence for the covalent binding of a reactive intermediate to the protein moiety.
G. Labbe (1989)
10.1021/BI00178A037
Identification of active-site peptides from 3H-labeled 2-ethynylnaphthalene-inactivated P450 2B1 and 2B4 using amino acid sequencing and mass spectrometry.
E. Roberts (1994)
Identification of activesite peptides from 3 Hlabeled 2ethynylnaphthaleneinactivated P 450 2 B 1 and 2 B 4 using amino acid sequencing and mass spectrometry
E. S. Roberts (1994)
Identification of active-site peptides
E. S. Roberts (1994)
Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor.
M. Chiba (1995)
10.1002/JHET.5570320431
A practical synthesis of 5‐(chloromethyl)furo[2,3‐b]pyridine, a key intermediate for the HIV protease inhibitor, L‐754,394
M. Bhupathy (1995)
Microsomal metabolism of the 5-lipoxygenase inhibitors L-746,530 and L-739,010 to reactive intermediates that covalently bind to protein: the role of the 6,8-dioxabicyclo[3.2.1]octanyl moiety.
N. Chauret (1995)
10.1006/ABBI.1995.9961
Mechanism-based inactivation of cytochrome P450 2B1 by 9-ethynylphenanthrene.
E. Roberts (1995)
10.1002/CHIN.199551178
A Practical Synthesis of 5-(Chloromethyl)furo(2,3-b)pyridine, a Key Intermediate for the HIV Protease Inhibitor, L-754,394.
M. Bhupathy (1995)
Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune
M. Chiba (1995)
10.1111/j.1600-0609.1996.tb01654.x
Mechanisms, chemical structures and drug metabolism
L. Pohl (1996)
10.1021/TX950177K
Identification of the heme adduct and an active site peptide modified during mechanism-based inactivation of rat liver cytochrome P450 2B1 by secobarbital.
K. He (1996)
10.1021/TX960060B
In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4.
Y. Sahali-Sahly (1996)
Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice.
D. Edwards (1996)
10.1021/TX950183G
Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: evidence for furan bioactivation.
K. Zhang (1996)
10.1021/TX950208B
Mechanism-based inactivation of hepatic ethoxyresorufin O-dealkylation activity by naturally occurring coumarins.
Y. Cai (1996)
10.1021/TX9700836
Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.
A. Munns (1997)
10.1016/S0960-894X(97)10043-9
Synthesis and biological evaluation of 6',7'-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4
F. H. Bellevue (1997)
Synthesis and biological evaluation of 6′,7′-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450
F. H. Bellevue (1997)
10.1021/TX970192K
Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice.
K. He (1998)
10.1006/ABBI.1998.0679
Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne.
E. Roberts (1998)
10.1021/BI981198R
Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins.
L. L. Koenigs (1998)
10.1016/S0891-5849(97)00463-2
Production of reactive oxygen species by microsomes enriched in specific human cytochrome P450 enzymes.
S. Puntarulo (1998)
10.1021/BI9823030
Electrospray ionization mass spectrometric analysis of intact cytochrome P450: identification of tienilic acid adducts to P450 2C9.
L. L. Koenigs (1999)
10.1021/BI992765T
Elucidation of distinct ligand binding sites for cytochrome P450 3A4.
N. Hosea (2000)
10.1021/BI992412U
Mechanism-based inactivation of cytochrome P450 3A4 by L-754,394.
L. Lightning (2000)
10.1021/TX990195S
Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry.
K. Regal (2000)
10.1016/S0011-393X(01)80093-X
Molecular mechanisms of adverse drug reactions
S. Nelson (2001)
10.1006/ABBI.2001.2390
Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A.
R. L. Moreno (2001)
10.1006/ABBI.2001.2401
Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.
M. Schrag (2001)
10.1021/JA027552X
Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site.
M. Dabrowski (2002)
10.1016/S0140-6736(02)11203-7
Clinical importance of the cytochromes P450
D. Nebert (2002)
10.1124/JPET.301.1.160
Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein.
H. Lin (2002)
10.1021/TX020052X
Mechanism-based inactivation of cytochromes P450 2E1 and 2E1 T303A by tert-butyl acetylenes: characterization of reactive intermediate adducts to the heme and apoprotein.
Anna L Blobaum (2002)
10.1016/S1570-0232(02)00172-1
Protein adducts: quantitative and qualitative aspects of their formation, analysis and applications.
M. Törnqvist (2002)
10.1124/DMD.30.7.845
Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4.
D. Stresser (2002)
10.2174/1389200023337054
The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans.
Danielson Pb (2002)
10.1016/S1570-0232(03)00399-4
Separation and detection methods for covalent drug-protein adducts.
Shufeng Zhou (2003)
10.1124/DMD.31.1.46
The mechanism-based inactivation of human cytochrome P450 2B6 by phencyclidine.
M. Jushchyshyn (2003)
10.1074/JBC.C400293200
The Structure of Human Microsomal Cytochrome P450 3A4 Determined by X-ray Crystallography to 2.05-Å Resolution*
J. Yano (2004)
10.1021/TX034199F
Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]- 4-[4-(trifluoromethyl)-2-pyridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction.
J. Hutzler (2004)
10.1021/TX034170B
Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development.
D. A. Evans (2004)
10.1126/SCIENCE.1099736
Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone
P. Williams (2004)
10.1021/TX034143L
Mechanism-based inactivation of cytochrome P450 3A4 by 4-ipomeanol.
T. Alvarez-Diez (2004)
Mechanism-based inactivation of cyto
J. M. Hutzler (2004)
Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P 450 2 E 1 and the mutant P 450 2 E 1 T 303 A
R. L. Moreno



This paper is referenced by
10.1124/dmd.119.089813
Mechanistic Studies of Cytochrome P450 3A4 Time Dependent Inhibition Using Two Cysteine- Targeting Electrophiles.
J. T. Barr (2020)
10.1070/RCR4447
Synthesis, transformations and biological properties of furo[2,3-b]pyridines
S. Sirakanyan (2015)
Mechanism-Based Inactivation of Human Cytochrome P 450 3 A 4 by Two Piperazine-Containing Compounds s
Amanda K. Bolles (2014)
10.1016/j.chembiol.2014.02.022
A crosslinker based on a tethered electrophile for mapping kinase-substrate networks.
Megan Riel-Mehan (2014)
10.1124/dmd.114.060459
Mechanism-Based Inactivation of Human Cytochrome P450 3A4 by Two Piperazine-Containing Compounds
Amanda K. Bolles (2014)
Role of genetic polymorphisms of drug metabolising enzymes in idiosyncratic drug reactions In vitro to in vivo translation
S. Dragović (2013)
10.1021/tx3003824
Reactive metabolites in the biotransformation of molecules containing a furan ring.
L. Peterson (2013)
10.1124/mol.112.080739
Cytochrome P450 Architecture and Cysteine Nucleophile Placement Impact Raloxifene-Mediated Mechanism-Based Inactivation
Brooke M. VandenBrink (2012)
10.1016/j.jpba.2012.04.035
Glutathione S-transferase pi trapping method for generation and characterization of drug-protein adducts in human liver microsomes using liquid chromatography-tandem mass spectrometry.
Hideo Yukinaga (2012)
10.1124/dmd.112.044560
Identification of the Residue in Human CYP3A4 That Is Covalently Modified by Bergamottin and the Reactive Intermediate That Contributes to the Grapefruit Juice Effect
Hsia-lien Lin (2012)
10.1016/J.APSB.2012.02.001
Protein target discovery of drug and its reactive intermediate metabolite by using proteomic strategy
Liang-hai Hu (2012)
10.1002/9780470921920.EDM113
Bioactivation and Reactive Metabolite Assays
W. Tang (2012)
10.1016/B978-0-12-381290-2.00001-X
Designing drugs to avoid toxicity.
G. Smith (2011)
10.1038/nrd3408
Managing the challenge of chemically reactive metabolites in drug development
B. K. Park (2011)
10.1124/dmd.110.037630
Substituted Imidazole of 5-Fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates Cytochrome P450 2D6 by Protein Adduction
L. D. Nagy (2011)
10.4155/bio.09.32
From known knowns to known unknowns: predicting in vivo drug metabolites.
O. Pelkonen (2009)
10.1002/9783527621460.CH9
Cytochrome P450s: Drug–Drug Interactions
D. Rock (2008)
10.14288/1.0066346
Structural characterization of superbug proteins involved in regulating beta-lactam resistance
M. S. Wilke (2008)
10.1021/TX700165Q
Identification of cytochrome P450 3A4 modification site with reactive metabolite using linear ion trap-Fourier transform mass spectrometry.
Hideo Yukinaga (2007)
10.1097/FTD.0b013e31815c16f5
Clinically Important Drug Interactions Potentially Involving Mechanism-based Inhibition of Cytochrome P450 3A4 and the Role of Therapeutic Drug Monitoring
Shu-feng Zhou (2007)
10.1002/JMS.1098
Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry.
Shuguang Ma (2006)
10.1021/TX0501738
Analysis of protein covalent modification by xenobiotics using a covert oxidatively activated tag: raloxifene proof-of-principle study.
Ju Liu (2005)
Semantic Scholar Logo Some data provided by SemanticScholar